Metabolic effects of fluoxetine in obese menopausal women

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Journal of Endocrinological Investigation

• Publication date

  2000-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF03343724PMID 10882145
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss

  1997cited by this paper
• A double-blind, placebo-controlled trial of the effect of fluoxetine on dietary intake in overweight women with and without binge-eating disorder.

  1996cited by this paper
• Fluoxetine increases resting energy expenditure and basal body temperature in humans.

  1995cited by this paper
• Overweight prevalence and trends for children and adolescents. The National Health and Nutrition Examination Surveys, 1963 to 1991.

  1995cited by this paper
• Fluoxetine in the Treatment of Obese Type 2 Diabetic Patients

  1994cited by this paper
• Determinants of decline in resting metabolic rate in aging females.

  1993cited by this paper
• The effect of fluoxetine on body weight, body composition and visceral fat accumulation.

  1993cited by this paper
• Physical activity is a significant predictor of body density in women.

  1993cited by this paper
• Clinical studies with fluoxetine in obesity.

  1992cited by this paper
• Fluoxetine treatment of the obese diabetic.

  1992cited by this paper
• An assessment of the thermogenic effects of fluoxetine in obese subjects.

  1992cited by this paper
• An assessment of the thermogenic effects of fluoxetine in obese subjects.

  1992cited by this paper
• Neuropeptides, appetite regulation, and human obesity.

  1991cited by this paper
• Fluoxetine's effect on weight loss in obese subjects.

  1991cited by this paper
• Reappraisal of the Weir equation for calculation of metabolic rate.

  1990cited by this paper
• Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study (with a commentary by Michael Weintraub).

  1989cited by this paper
• Effect of γ-Irradiation on Mouse Pancreatic Islet-Allograft Survival

  1989cited by this paper
• Serotoninergic modulation of the pattern of eating and the profile of hunger-satiety in humans.

  1987cited by this paper
• Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity.

  1987cited by this paper
• Fluoxetine-induced weight loss in overweight non-depressed humans.

  1987cited by this paper
• 24-hour energy expenditure and the menstrual cycle.

  1986cited by this paper
• A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder.

  1985cited by this paper
• Norepinephrine, clonidine, and tricyclic antidepressants selectively stimulate carbohydrate ingestion through noradrenergic system of the paraventricular nucleus.

  1985cited by this paper
• The pharmacologic profile of fluoxetine.

  1985cited by this paper
• Fluoxetine kinetics and protein binding in normal and impaired renal function

  1984cited by this paper

• Use of Fluoxetine to Reduce Weight in Adults with Overweight or Obesity: Abridged Republication of the Cochrane Systematic Review

  2022cites this paper
• Fluoxetine for adults who are overweight or obese.

  2019cites this paper
• The Impact of Antidepressant Therapy on Glycemic Control in Canadian Primary Care Patients With Diabetes Mellitus

  2018cites this paper
• Glucose metabolism and antidepressant medication.

  2012cites this paper
• Early life handling decreases serotonin turnover in the nucleus accumbens and affects feeding behavior of adult rats.

  2010cites this paper
• Cyclic progestin administration increases energy expenditure and decreases body fat mass in perimenopausal women

  2006cites this paper
• Medication effects on metabolic rate: a systematic review (part 2).

  2005cites this paper
• Monoaminergic‐based Pharmacotherapy for Depression

  2005cites this paper
• The psychopharmacotherapy of anorexia nervosa: Clinical, neuroendocrine and metabolic aspects

  2004cites this paper
• Psychotropic Drugs in the Treatment of Obesity

  2004cites this paper
• The use of SSRIs in depressive disorders specific to women.

  2002cites this paper